5 Participants Needed

IPD Probe for Gut Permeability

AC
AG
Overseen ByAnna Gao, RN
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to examine the feasibility of using a trans-nasal IPD probe as a measurement tool for gut permeability

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications, such as those that delay gastric emptying, impair clotting, nasal steroids, antibiotics, H2 Histamine Antagonists, and Mast Cell stabilizers. If you are on any of these, you would need to stop them to participate.

Is the IPD Probe for Gut Permeability safe for humans?

The research does not provide specific safety data for the IPD Probe in humans, but it discusses the importance of monitoring gut barrier integrity and suggests that certain markers can help detect changes early. This implies that safety assessments are crucial, but no direct human safety data is available from the provided studies.12345

How does the IPD Probe for Gut Permeability treatment differ from other treatments for gut permeability?

The IPD Probe for Gut Permeability is unique because it offers a minimally invasive way to measure gut permeability in real-time using gut potential difference (GPD) measurement, unlike traditional dual sugar absorption tests that are less precise and harder to use in certain populations like infants. This method allows for localized assessment of gut permeability, which can help identify different disease severities or pathologies.24678

What data supports the effectiveness of the IPD Probe treatment for gut permeability?

The research on a minimally invasive probe for gut permeability suggests it can provide real-time localized evaluation, which may offer advantages over traditional methods like the dual sugar absorption tests. This could potentially improve the assessment of gut permeability in various conditions, including inflammatory bowel diseases.2391011

Who Is on the Research Team?

GT

Guillermo Tearney, M.D, PhD.

Principal Investigator

Massachusetts General Hospital

Are You a Good Fit for This Trial?

This trial is for healthy adults aged 18-60 who can consent and fast for at least 8 hours. It's not suitable for those with respiratory diseases, nasal steroid use, gastric emptying delays, alcoholism, certain medication uses (like clotting impairments or mast cell stabilizers), recent antibiotics use, liver diseases, galactosemia, uncontrolled diabetes, lactation due to pregnancy or any contraindications to nasopharyngeal procedures.

Inclusion Criteria

Subject must fast (no solid food) for at least 8 hours prior to the procedure
I can understand and agree to the treatment plan.
People who are in good health and do not have any medical conditions.

Exclusion Criteria

I have been diagnosed with or suspected to have Galactosemia.
I am on medication that slows down my stomach emptying.
I am currently taking medication for heartburn or ulcers.
See 14 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Procedure

Participants undergo the trans-nasal IPD probe procedure to measure intestinal potential difference and image quality

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the procedure

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • IPD Probe via TNIT
Trial Overview The study is testing the feasibility of a trans-nasal IPD probe as a tool to measure gut permeability. Participants will undergo this minimally invasive procedure where the probe is inserted through the nose to assess intestinal function.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Feasibility of trans-nasal IPD probeExperimental Treatment1 Intervention
The purpose of this study is to examine the feasibility of using a trans-nasal IPD probe as a measurement tool for gut permeability

Find a Clinic Near You

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials
3,066
Recruited
13,430,000+

Citations

Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test. [2022]
The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease. [2019]
Intestinal permeability in patients with Crohn's disease and their first-degree relatives. [2015]
Minimally Invasive Image-Guided Gut Transport Function Measurement Probe. [2023]
Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease. [2021]
Translational safety biomarkers of colonic barrier integrity in the rat. [2021]
Fecal and Circulating Biomarkers for the Non-Invasive Assessment of Intestinal Permeability. [2023]
Ex vivo intestinal permeability assay (X-IPA) for tracking barrier function dynamics. [2023]
Intestinal permeability assessment using lactulose and mannitol in celiac disease. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
The relationship between rat intestinal permeability and hydrophilic probe size. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Transdermal fluorescence detection of a dual fluorophore system for noninvasive point-of-care gastrointestinal permeability measurement. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security